Literature DB >> 16376618

Optimization of CD34+ collection for autologous transplantation using the evolution of peripheral blood cell counts after mobilization with chemotherapy and G-CSF.

M T Delamain1, K Metze, J F C Marques, A R C Reis, C A De Souza, I Lorand-Metze.   

Abstract

BACKGROUND: Peripheral blood progenitor cells (PBPC) collection after high dose chemotherapy can be influenced by several factors. We searched for parameters that may predict the best day to start harvesting of PBPC in order to collect most CD34+ cells with the least number of aphereses.
METHODS: We studied patients who underwent mobilization chemotherapy for autologous transplantation. The influence of age, sex, diagnosis, number of previous chemotherapy cycles, peripheral blood (PB) counts at day of mobilization (D0), day of neutrophils <1.0 x 10(9) l(-1) and day of nadir and interval between both (delta) on harvesting was investigated. Multivariate linear correlation models were built to predict the best harvesting with principles of parsimony. In patients where sequential CD34+ cell count was performed, the theoretical day of peak was calculated by interpolation in polynomial regression.
RESULTS: One hundred and thirty four patients entered the analysis: 36 Hodgkin's lymphoma (HL), 65 B-large cell lymphoma (NHL) and 33 multiple myeloma (MM). Day of harvesting correlated with nr CHT, hemoglobin on D0, day of granulocytes <1.0 x 10(9) l(-1), delta and dosis of mobilization therapy. The day of CD34+ peak could be calculated by the formula = (-0.41) x Hemoglobin D0 + (day peripheral CD34+ cells = 10 x 10(6) microl(-1)) x 0.99 + 7.8. This model could explain 81% of the variance of the peak day and was stable by bootstrap resampling. Day of peripheral CD34+ cells = 10 x 10(6) microl(-1) preceded the calculated peak by 3-9 days.
CONCLUSIONS: Although the day of best collection can be predicted using only sequential PB counts after mobilization chemotherapy, a model of prediction using peripheral CD34+ cell count is important especially for optimizing collection in poor mobilizing patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16376618     DOI: 10.1016/j.transci.2005.09.004

Source DB:  PubMed          Journal:  Transfus Apher Sci        ISSN: 1473-0502            Impact factor:   1.764


  4 in total

1.  Peripheral hematopoietic progenitor cell mobilization for autologous transplantation in hematologic malignancies.

Authors:  José Francisco Comenalli Marques
Journal:  Rev Bras Hematol Hemoter       Date:  2011

Review 2.  Toward personalized cell therapies by using stem cells: seven relevant topics for safety and success in stem cell therapy.

Authors:  Fernando de Sá Silva; Paula Nascimento Almeida; João Vitor Paes Rettore; Claudinéia Pereira Maranduba; Camila Maurmann de Souza; Gustavo Torres de Souza; Rafaella de Souza Salomão Zanette; Sueli Patricia Harumi Miyagi; Marcelo de Oliveira Santos; Márcia Martins Marques; Carlos Magno da Costa Maranduba
Journal:  J Biomed Biotechnol       Date:  2012-11-20

3.  Lymph vascular invasion in invasive mammary carcinomas identified by the endothelial lymphatic marker D2-40 is associated with other indicators of poor prognosis.

Authors:  Vanessa F Z Marinho; Konradin Metze; Fernanda S F Sanches; Gislene F S Rocha; Helenice Gobbi
Journal:  BMC Cancer       Date:  2008-02-29       Impact factor: 4.430

4.  Immunophenotyping in myelodysplastic syndromes can add prognostic information to well-established and new clinical scores.

Authors:  Suiellen C Reis-Alves; Fabíola Traina; Guilherme Harada; Paula M Campos; Sara T O Saad; Konradin Metze; Irene Lorand-Metze
Journal:  PLoS One       Date:  2013-12-06       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.